| Mitchell Eugene Huelsing, DPT | |
|
206b Oxford Rd, New Albany, MS 38652-3115 | |
| (662) 534-4445 | |
| (901) 850-5226 |
| Full Name | Mitchell Eugene Huelsing |
|---|---|
| Gender | Male |
| Speciality | Physical Therapy |
| Experience | 7 Years |
| Location | 206b Oxford Rd, New Albany, Mississippi |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285155176 | NPI | - | NPPES |
| 11381 | Other | TN | STATE PT LICENSE |
| 6603 | Other | MS | STATE PT LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | 11381 (Tennessee) | Secondary |
| 208100000X | Physical Medicine & Rehabilitation | 6603 (Mississippi) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Athletico Ltd | 4789602681 | 1957 |
News Archive
Researchers have developed an artificial intelligence platform to detect a range of neurodegenerative disease in human brain tissue samples, including Alzheimer's disease and chronic traumatic encephalopathy, according to a study conducted at the Icahn School of Medicine at Mount Sinai and published in the Nature medical journal Laboratory Investigation.
With the world's population projected to hit 9.9 billion by 2050, experts are continuing to look for sustainable food sources to feed the masses.
For women seeking pregnancy by assisted reproductive technologies, such as in-vitro fertilization, a new study shows that the health of the uterus is more relevant than egg quality for a newborn to achieve normal birth weight and full gestation.
Alcyone Lifesciences, Inc., a leader in neural intervention systems for neurological conditions and targeted drug delivery, and DNAtrix Inc., a privately held biotechnology company and a leader in oncolytic virus therapy, have entered into an exclusive clinical collaboration. Under the agreement, DNAtrix will utilize Alcyone's MEMS Cannula (AMC) targeted delivery platform for the intratumoral delivery of DNX-2401, an oncolytic adenovirus and DNAtrix's lead product for the treatment of the most aggressive form of brain cancer, glioblastoma (GBM).
› Verified 4 days ago
| Entity Name | Athletico Ltd |
|---|---|
| Entity Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Entity Identifiers | NPI Number: 1477224814 PECOS PAC ID: 4789602681 Enrollment ID: O20211115001046 |
News Archive
Researchers have developed an artificial intelligence platform to detect a range of neurodegenerative disease in human brain tissue samples, including Alzheimer's disease and chronic traumatic encephalopathy, according to a study conducted at the Icahn School of Medicine at Mount Sinai and published in the Nature medical journal Laboratory Investigation.
With the world's population projected to hit 9.9 billion by 2050, experts are continuing to look for sustainable food sources to feed the masses.
For women seeking pregnancy by assisted reproductive technologies, such as in-vitro fertilization, a new study shows that the health of the uterus is more relevant than egg quality for a newborn to achieve normal birth weight and full gestation.
Alcyone Lifesciences, Inc., a leader in neural intervention systems for neurological conditions and targeted drug delivery, and DNAtrix Inc., a privately held biotechnology company and a leader in oncolytic virus therapy, have entered into an exclusive clinical collaboration. Under the agreement, DNAtrix will utilize Alcyone's MEMS Cannula (AMC) targeted delivery platform for the intratumoral delivery of DNX-2401, an oncolytic adenovirus and DNAtrix's lead product for the treatment of the most aggressive form of brain cancer, glioblastoma (GBM).
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mitchell Eugene Huelsing, DPT 206b Oxford Rd, New Albany, MS 38652-3115 Ph: (662) 534-4445 | Mitchell Eugene Huelsing, DPT 206b Oxford Rd, New Albany, MS 38652-3115 Ph: (662) 534-4445 |
News Archive
Researchers have developed an artificial intelligence platform to detect a range of neurodegenerative disease in human brain tissue samples, including Alzheimer's disease and chronic traumatic encephalopathy, according to a study conducted at the Icahn School of Medicine at Mount Sinai and published in the Nature medical journal Laboratory Investigation.
With the world's population projected to hit 9.9 billion by 2050, experts are continuing to look for sustainable food sources to feed the masses.
For women seeking pregnancy by assisted reproductive technologies, such as in-vitro fertilization, a new study shows that the health of the uterus is more relevant than egg quality for a newborn to achieve normal birth weight and full gestation.
Alcyone Lifesciences, Inc., a leader in neural intervention systems for neurological conditions and targeted drug delivery, and DNAtrix Inc., a privately held biotechnology company and a leader in oncolytic virus therapy, have entered into an exclusive clinical collaboration. Under the agreement, DNAtrix will utilize Alcyone's MEMS Cannula (AMC) targeted delivery platform for the intratumoral delivery of DNX-2401, an oncolytic adenovirus and DNAtrix's lead product for the treatment of the most aggressive form of brain cancer, glioblastoma (GBM).
› Verified 4 days ago